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ABSTRACT 
Background 
Pre-eclampsia and its complications remain a significant cause of maternal and perinatal 
morbidity and mortality on a global level. There are few data regarding the maternal and fetal 
outcome of pre-eclampsia at term. Studies suggest that poor maternal outcome is more 
prevalent as one approaches term, while there are conflicting findings regarding the outcomes 
of the babies born to term pre-eclamptic patients.  
Objective  
To determine the prevalence of pre-eclampsia in term pregnancies at Rahima Moosa Mother 
and Child Hospital (RMMCH), a hospital that provides district and higher level referral 
services, and to assess the severity of maternal disease in pre-eclampsia at term, as well as 
fetal outcomes. 
 
Methods  
This was a prospective cross-sectional, descriptive study on women giving birth at term with 
pre-eclampsia. All women were followed up until delivery. The indication for and mode of 
delivery, maternal progress and complications, as well as fetal outcome, were recorded. 
 
Results 
Seventy-eight patients were entered into the study, giving a hospital prevalence rate of pre-
eclampsia at term of 1.2%. The major maternal complications were those of severe 
hypertension (75.6%), eclampsia (9%), HELLP syndrome (3.8%), and pulmonary oedema 
(7.7%). There was one maternal death. Fifty-one patients (65%) delivered by caesarean 
section. Major fetal complications encountered were respiratory distress (7.5%) and birth 
asphyxia (3.7%). There was one neonatal death from meconium aspiration.  
VII 
 
 
Conclusion   
This study revealed a significant number of patients having major maternal as well as fetal 
complications of pre-eclampsia at term. Larger epidemiological studies are needed to predict 
maternal and fetal outcomes in term pre-eclamptic patients. 
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DEFINITIONS 
 
Anaemia  A haemoglobin concentration <11 g/dL 
Atypical pre-eclampsia Exists when the woman has all the aspects of the syndrome but 
without hypertension or proteinuria, or both 
Eclampsia The onset of generalized convulsions associated with signs of 
pre-eclampsia during pregnancy, labour or within 7 days of 
delivery. All other causes of convulsive disorders must be 
ruled out 
HELLP syndrome The biochemical and haematological abnormalities: 
haemolysis quantified by an elevated lactate dehydrogenase 
level, elevated liver enzymes(AST and ALT >40 IU/L) and 
thrombocytopenia(<150 x 10
9 
/L) in association with pre-
eclampsia 
Hypertension 
 
A systolic BP ≥140 mmHg or a diastolic BP ≥90 mmHg. (An 
elevation of a systolic BP >30mmHg and diastolic >15 mmHg, 
no longer suffices but rather warrants close monitoring) 
Intra-uterine growth 
restriction 
The inability of a fetus to grow to its full genetic potential, 
usually due to placental insufficiency with a subsequent birth 
weight below the 10
th
 percentile for gestational age 
Low birth weight Birth weight <2500 g 
Maternal near-miss A woman who nearly died but survived a complication that 
occurred during pregnancy, childbirth or within 42 days of 
termination of pregnancy 
Moderate 
thrombocytopenia 
Platelet count <100 x 10
9 
/L but ≥50 x 109/L 
Neonatal unit  A facility dedicated to newborn babies where interventions 
ranging from respiratory support to observation of certain 
parameters of a distressed baby are offered 
Oligohydramnios A decreased amniotic fluid index ≤5 cm 
Photopsia The perception of flashing lights 
Postpartum haemorrhage Blood loss ≥500 mL at vaginal delivery or ≥1000 mL at 
caesarean section   
Pre-eclampsia De novo hypertension after 20 weeks’ gestation, returning to 
normal postpartum, and properly documented abnormal 
proteinuria(it must be born in mind that several definitions 
exists but the above is the consensus used for the purpose of 
this research) 
Proteinuria  ≥300 mg/day (equivalent to 1+ on dipstick), or spot urine 
protein of 3 mg/dL urine, or spot protein/creatinine ratio ≥30 
mg/mmol 
Scotoma A defect of vision in a defined area of the visual field 
occurring in one or both eyes 
Severe hypertension Systolic BP≥160 mmHg or diastolic BP≥110 mmHg, on two 
occasions four hours apart or a single diastolic BP≥120 mmHg 
Severe maternal morbidity A concept that reflects the extent of maternal complications 
such as transfusions, eclampsia, hysterectomy, cardiac events, 
mechanical ventilation, septicaemia, renal failure, stroke, 
haemorrhagic shock and pulmonary embolism 
X 
 
Severe thrombocytopenia Platelet count <50 x 10
9
/L 
Small for gestational age A birth weight below the 10
th
 percentile for gestational age for 
a specific population 
Superimposed pre-
eclampsia 
Patients diagnosed with hypertension before 20 weeks’ 
gestation, with new onset proteinuria, a sudden increase in 
hypertension or the development of HELLP syndrome, after 
20 weeks’ gestation 
Term pregnancy A pregnancy that is ≥37 completed weeks of gestation 
Thrombocytopenia Platelet count <150 x 10
9
/L 
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1.0 INTRODUCTION  
“She gave life. She is a wife. She is a mother and she is a friend. She is a sister, a survivor to 
the end.” (Ashanti Holliday)(1). All this she is and so much more, what do we do to protect 
her? Do we dare to care?  
 
It is estimated that 342 900 women die worldwide from pregnancy-related causes (2).  
Pre-eclampsia and its complications remain a significant cause of maternal and perinatal 
morbidity and mortality. Globally, pre-eclampsia complicates 2-8% of pregnancies, and 10-
15% of direct maternal deaths are pre-eclampsia-related(3). In South Africa, according to the 
Saving Mothers report of 2008-2010, hypertensive disorders are the second commonest direct 
cause of maternal deaths (14%) (4). It has been reported that pre-eclampsia and gestational 
hypertension make up a significant 70% of hypertensive disorders of pregnancy (5). 
 
Pre-eclampsia is a multi-system disease. Although the exact cause is unknown, evidence 
shows that it arises from the incomplete invasion of the trophoblast, which subsequently 
results in vasospasm, endothelial dysfunction and ischaemia (6). The disease predominantly 
affects the circulatory system, the renal system, the central nervous system, coagulation and 
liver (7).  
Management entails admission to hospital and stabilisation of blood pressure with 
antihypertensive agents if necessary. The patient is assessed clinically, blood and urine are 
analysed, and an ultrasound and non-stress test are done to assess the viability and well-being 
of the fetus (7). These investigations give an indication of the severity of disease and guide 
the further management. The only cure for pre-eclampsia is delivery. 
Maternal complications include pulmonary oedema, renal failure, liver failure or rupture, 
disseminated intravascular coagulopathy, HELLP syndrome, placental abruption, 
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cerebrovascular accidents, eclampsia and death (7). Fetal growth impairment, placental 
abruption and perinatal mortality are a consequence of ischaemia due to decreased 
uteroplacental blood flow.  
 
It has been proposed that pre-eclamptic patients who present at term may have normal to 
increased utero-placental flow, sparing the fetus from the complications of placental 
insufficiency that often characterises pre-eclampsia of earlier onset (8). This hypothesis 
creates the need to explore the outcome of this population of pre-eclamptic patients at term. 
The literature is abundant with studies looking at pre-eclampsia and comparing immediate 
and delayed delivery of such patients. However, the dilemma of immediate delivery versus 
delaying for maturity of the baby does not exist in the pre-eclamptic patient at ≥37 weeks’ 
gestation because there is consensus that delivery should be expedited in such women(7).  
The aim of this study was to determine the prevalence of pre-eclampsia at term at Rahima 
Moosa Mother and Child Hospital (RMMCH), a tertiary level hospital that serves the areas 
around Coronationville in Johannesburg. In view of the above-mentioned hypothesis that pre-
eclamptic patients at term have a near normal utero-placental flow compared with those who 
have early-onset pre-eclampsia, the researcher felt compelled to assess the maternal and fetal 
outcome in this specific population of pre-eclamptic women.  
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2.0 LITERATURE REVIEW  
Although the literature is overwhelmed with data on pre-eclampsia, it becomes apparent that 
little work has been undertaken to show the outcome of the pre-eclamptic pregnancy at term.  
Over the past 20-odd years a large amount of work has been carried out in Africa, Asia, Latin 
America and the Caribbean, in which this “ongoing holocaust” is described to be killing 10-
15% of mothers(3). According to the South African Saving Mothers report of 2008-2010, 
there was a small reduction in deaths due to complications of hypertension, compared to the 
previous triennium (4). However, no mention was made of the gestation of pregnancy at 
which these outcomes were documented.  
 
2.1 Epidemiology 
Pre-eclampsia complicates 2-8% of pregnancies worldwide (3). The prevalence varies 
according to geographic regions of the world, ranging from 2.5% in Saudi Arabia to 4.3% in 
Turkey, to 5-8% in the USA (6,9,10). This variation may be attributed to racial differences, 
socioeconomic status and other demographic parameters such as age and parity (10). Pre-
eclampsia is described as a disease predominantly affecting nulliparous women, and women 
at the extremes of their reproductive ages (<20 and >40 years) (9). The exact prevalence of 
pre-eclampsia in South Africa is unknown, although a 5-year prospective study in Cape Town 
reported a prevalence of 7.1% (11). 
 
A 10 year retrospective study in Saudi Arabia showed that 42% of pre-eclamptic patients 
were primigravid (9). Pregnancy, even if it is terminated early, offers some form of immunity 
to pre-eclampsia in the next pregnancy (12). However, it has been shown that the protective 
effect of multiparity is lost with a change of partner and also raises the concept of 
primipaternity rather than primigravidity (11). 
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Extremes of maternal age, multiple pregnancy, previous pre-eclampsia, chronic hypertension, 
pre-gestational diabetes, vascular and connective tissue disorder, nephropathy and 
antiphospholipid syndrome are conditions that predispose a pregnant woman to develop pre-
eclampsia. In obesity, although the pathophysiology is unknown, the increased risk for 
developing pre-eclampsia is postulated to be due to the oxidative stress, inflammation and 
altered vascular function that have been reported in obese women (13). 
 
African-American race or black race has been shown to be a predisposing factor (6,14). 
The older literature reports cases of pre-eclampsia in close relatives, however some authors 
have argued that this was owing to the commonality of the condition and could just as well be 
coincidental (12). Decades later, the genetic factor still remains and has repeatedly been 
shown to be a predisposing component to pre-eclampsia (6).  
 
2.2 Definitions and criteria for the severity of pre-eclampsia 
The importance of classifying the severity of pre-eclampsia arises when one is faced with an 
ill patient who is still remote from  term gestation. The definitions used in this research report 
are provided in the list of definitions at the beginning of the report. In the clinical situation, a 
decision on classification of a patient’s hypertensive disorder has to be made taking into 
consideration the patient’s clinical condition and risks of morbidity and mortality, as well as 
delivering a pre-term baby, which has its own consequences. Various classifications exist in 
which there are criteria to define severe pre-eclampsia. The alternative to those criteria 
defined as severe are accepted as mild or moderate as they are not specifically defined. Table 
1 shows the most recent criteria as accepted by the ACOG (15). 
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Table 1. Criteria that are features of severe pre-eclampsia 
 
Symptoms of central nervous system dysfunction: 
       New onset cerebral or visual disturbance, such as: 
 Photopsia, scotomata, cortical blindness, retinal vasospasm 
 Severe headache, or headache that persists and progresses despite analgesic therapy 
 Altered mental status 
 
Hepatic abnormality: 
        Severe persistent right upper quadrant or epigastric pain unresponsive to 
        medication and not accounted for by an alternative diagnosis  or serum    
        aminotransferase concentration ≥ twice normal, or both 
 
Severe blood pressure elevation: 
       Systolic BP≥ 160 mmHg or diastolic BP≥ 110 mmHg on two occasions at least four 
       hours apart while the patient is on bedrest (unless the patient is on anti-hypertensive   
       therapy) 
 
Thrombocytopenia: 
     Platelet count <100x10
9
/L  
 
Renal abnormality: 
Progressive renal insufficiency (serum creatinine >97 μmol/L or doubling  of serum 
creatinine concentration in the absence of other renal disease) 
 
Pulmonary oedema 
 
 
 
2.3 Pathophysiology  
Pre-eclampsia is described as a syndrome unique to pregnancy that can affect every organ 
system. Although the precise aetiology remains elusive, pre-eclampsia has been a topic of 
research for a very long time, and a number of theories for its pathogenesis have been 
proposed. Current research has led to the understanding that it is a two-stage disorder. The 
incomplete or abnormal trophoblastic invasion sets the scene for stage one, the placental 
disease. In normal placentation, uterine spiral arterioles undergo extensive remodelling by 
trophoblastic invasion, leading to formation of wide-bore vessels carrying maternal blood to 
the placenta. In pre-eclampsia, there is incomplete trophoblastic invasion, and therefore the 
normal pregnancy remodelling of maternal vessels does not happen. This results in the deeper 
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myometrial arterioles maintaining their pre-pregnancy anatomical structure, thus remaining 
narrow conduits of blood flow. Their mean external diameter is half that of vessels in normal 
placentas (16). The effect of these abnormally narrowed spiral arterioles is placental 
hypoperfusion and hypoxia. Stage two is the maternal clinical syndrome. The placental 
disease leads to a release of trophoblastic debris, apoptotic cells and anti-angiogenic factors, 
which induce a maternal systemic inflammatory response and widespread endothelial 
vascular damage, producing the pre-eclampsia syndrome of high blood pressure, proteinuria 
and organ dysfunction (16).  
 
2.3.1 Vasospasm and haemoconcentration  
Intense vasospasm with endothelial damage and dysfunction in the maternal circulation is 
caused by the interaction of various vasoactive agents such as prostacyclin (vasodilator), 
thromboxane A2 (potent vasoconstrictor), nitric oxide (potent vasodilator), and endothelins 
(potent vasoconstrictors) (6). In pre-eclampsia, compared with normal pregnancy, 
prostacyclin production decreases, while thromboxane A2 production by platelets is 
increased, with subsequent increased vascular resistance and hypertension (16). The 
simultaneous endothelial cell damage results in: 1) decreased production of nitric oxide and 
release of substances that promote coagulation and increase sensitivity to vasopressors; and 
2) a capillary leak of blood constituents, which are deposited subendothelially. This results in 
haemoconcentration, decreased colloid osmotic pressure, and contraction of the intravascular 
space. As the endothelium undergoes repair after delivery, the vasoconstriction resolves, and 
there is a concomitant decrease in the haematocrit levels as the blood volume increases (6). 
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2.3.2 Haematological changes 
A commonly identified abnormality in pre-eclampsia is thrombocytopenia. The intensity may 
vary according to the severity of the pre-eclampsia. The lower platelet count is associated 
with higher maternal and fetal morbidity and mortality (17). The thrombocytopenia usually 
worsens with ongoing pregnancy. After delivery, the decline in platelet count may continue 
for 48-72 hours. The platelet count then increases gradually and within three to five days 
should reach normal levels. Haemolysis may also occur simultaneously with the 
thrombocytopenia. This is reflected by a disproportionate rise in lactate dehydrogenase in the 
serum (6), and the presence of schizocytosis, spherocytosis and reticulocytosis on a 
peripheral blood smear. The most sensitive objective marker of haemolysis is a reduced 
serum haptoglobin level (18,19). 
 
2.3.3 Hepatic changes 
Patients with severe pre-eclampsia may have significantly altered hepatic function (6). 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels may be 
elevated and inversely follow platelet counts. They also usually normalize within three days 
after delivery. Hyperbilirubinaemia may occur especially when haemolysis is present. 
Autopsy studies have found that the characteristic lesion commonly found is hepatic 
infarction and periportal haemorrhage in the liver lobule periphery (16,20). Hepatic 
haemorrhage may extend to form a subcapsular haematoma that presents clinically as right 
upper abdominal pain. Hepatic rupture is rare but life-threatening, requiring emergency 
surgical intervention (6,18). 
 
HELLP syndrome, a variant of severe pre-eclampsia, is associated with substantial mortality 
and morbidity. It diagnosis is based on laboratory abnormalities. The syndrome has been 
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reported to occur in 20% of women with severe pre-eclampsia (18). Maternal mortality 
ranges from 0-4% (18). Other complications associated with HELLP syndrome include acute 
renal failure in 8% of women, pulmonary oedema in 6%, and subcapsular liver haematoma in 
1% (18).  Due to the unfavourable cervix and early gestation found in most patients with 
HELLP syndrome, caesarean delivery is commonly performed. Wound haematoma and 
subsequent wound sepsis becomes a further complication in this group of patients, due to the 
low platelet count (18). 
 
2.3.4 Renal changes 
In normal pregnancy, there is an increase in renal blood flow with increased glomerular 
filtration and decreased serum creatinine level. However, due to the vasospasm in pre-
eclampsia this physiological change does not occur. Instead, there is decreased glomerular 
filtration which, together with the haemoconcentration, leads to oliguria and a rise in serum 
creatinine level. In the glomeruli, there is podocyte dysfunction and endothelial swelling, also 
termed glomerular capillary endotheliosis, which causes an increase in the permeability of the 
membrane with subsequent protein leakage into the urine (6).  
 
Acute renal failure is a rare complication of pre-eclampsia and usually resolves 
spontaneously after delivery (21), although dialysis may occasionally be required. More 
frequently, acute tubular necrosis is precipitated by haemorrhagic shock which accompanies 
the other complications mentioned above, mainly placental abruption (21). Rarely, 
irreversible renal cortical necrosis develops. A five-year prospective study in the United 
Kingdom showed that 0.55% of women with pre-eclampsia required dialysis based on 
worsening creatinine levels (22). A prospective case series in Tygerberg Hospital, Cape 
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Town, reported that 6 out of 340 pre-eclamptic patients (1.7%) had severe renal impairment, 
of whom one required dialysis (11).  
 
2.3.5 Neurological changes 
Changes to the cerebral circulation are the primary effectors of the neurological symptoms 
seen in pre-eclamptic patients. Normally, by the mechanism of autoregulation, cerebral blood 
flow is maintained at a constant rate despite changes in cerebral perfusion pressures. Blood 
pressures above and below the autoregulatory limits result in this mechanism being lost. In 
the case of an acute hypertensive episode at pressures above the autoregulatory limit, the 
excessive intravascular pressure overcomes the constriction of the vascular smooth muscle 
with subsequent forced dilatation of the cerebral vessels. This loss in autoregulation results in 
hyperperfusion and disruption of the blood-brain barrier with resultant vasogenic oedema, as 
plasma constituents leave the vasculature and expand the extra-cellular space (23). This 
forms the underlying cause of eclampsia and hypertensive encephalopathy (23).  
 
Generalised seizures occur in the presence of excessive release of excitatory 
neurotransmitters, massive depolarization of network neurons, and bursts of action 
potentials(16). In the pre-eclamptic patient  this manifests as generalized tonic-clonic 
convulsions and in the absence of other neurologic conditions is known as eclampsia. 
Morbidity to both mother and fetus is increased and prolonged seizures can cause significant 
brain injury and later brain dysfunction(16).  
Eclampsia can occur antepartum, intrapartum or postpartum and is most common in the third 
trimester with an increase in frequency as term approaches (24). Although uncommon in 
Europe with a reported prevalence of 2-3 cases per 10 000 births, it occurs more frequently in 
developing countries, with an estimated 16-69 cases per 10 000 births (3). Eclampsia is a 
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major cause of morbidity and mortality worldwide and accounts for more than 50 000 
maternal deaths annually (25). The case fatality rate of eclampsia is 3-5% in low and middle 
income countries compared to 1% in developed countries (3,5). A three-year review from an 
academic hospital in Nigeria showed a prevalence of 13 per 1000 deliveries, with a case 
fatality rate of 8.5% (25). A retrospective analysis done in Durban showed an increase in the 
prevalence of eclampsia from 2.8 per 1000 deliveries to 6 per 1000 deliveries from 1980 to 
1990. However, in the same period there was a slight decline in the case fatality rate from 
12% to 9% (26). The high morbidity and mortality was attributed to low socioeconomic 
status, delayed referral to tertiary institution, non-availability of transport facilities and 
unbooked status of patients (25,26). 
  
Another recently described phenomenon is the posterior reversible encephalopathy syndrome 
(PRES). Although its exact cause is unclear, it is thought to occur with disrupted 
autoregulation and endothelial dysfunction with or without subsequent vasogenic oedema 
(27). PRES is typically associated with severe hypertension but has also been described in 
patients with endothelial damage who experience rapid increases in blood pressure (28). 
Insidious onset of headaches, altered levels of consciousness, visual changes and seizures, 
associated with characteristic neuroimaging findings of posterior cerebral white matter 
describes this clinical syndrome. Reversibility is most frequent if PRES is promptly 
recognized and treated, however its effects may not always be reversible and its location may 
not necessarily be confined to the posterior regions of the brain (24,27).  
 
Intracerebral haemorrhage, resulting from severe systolic or diastolic hypertension or sudden 
increases in blood pressure, has been reported to be the commonest cause of maternal 
mortality from hypertensive disorders of pregnancy, irrespective of the occurrence of 
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eclampsia (29). Diastolic blood pressures  above 110 mmHg and persistent systolic values 
higher than 160 mmHg have been associated with significant risk of complications, which 
may result in PRES, eclampsia, stroke or all three (29). 
 
Clinically evident neurological manifestations in patients without eclampsia or stroke include 
headaches, visual disturbances, and generalized hyperreflexia (24), which tend to resolve 
after the administration of magnesium sulphate. Blindness is rare and may be transient (9). 
The loss or disturbance of consciousness associated with eclampsia from the seizure itself, 
PRES or an intra-cerebral haemorrhage, may require intensive care unit admission with 
intubation and ventilation (26). 
 
2.3.6 Pulmonary oedema 
Pulmonary oedema is reported as the fourth commonest cause of maternal mortality in the 
United Kingdom. A review in 2012 showed estimated rates of acute pulmonary oedema in 
pregnancy of 0.08% to 0.5% (30). A five-year prospective study in the United Kingdom 
showed a prevalence of pulmonary oedema of 1.2 per 10 000 deliveries (25 out of 210 631 
patients) (22). The aetiology is multi-factorial, often being a combination of left ventricular 
failure and non-cardiogenic pulmonary oedema. In some women, pulmonary oedema occurs 
as a result of increased hydrostatic pressure and a decreased colloid osmotic pressure 
resulting in fluid accumulation in the lung parenchyma, especially in the postpartum period 
(29, 30). Other women may demonstrate increased capillary permeability, and in some 
patients acute pulmonary oedema may be caused by iatrogenic fluid volume overload (24). 
Breathing and oxygenation is subsequently compromised, manifesting as severe respiratory 
distress that may require intubation. There are few studies demonstrating pulmonary oedema 
in pre-eclamptic women, let alone pre-eclamptic women at term (30).  
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2.3.7 Placental complications 
Due to the compromised uteroplacental perfusion following the abnormal trophoblastic 
invasion, manifestations of pre-eclampsia can also be seen in the fetal-placental unit. This is a 
major contributor to the increase in perinatal morbidity and mortality rates. By 16 weeks of 
gestation, the vascular resistance in the uterine artery decreases markedly in normal 
placentation. However, in pre-eclampsia the abnormal placentation results in the vascular 
resistance remaining abnormally high, which subsequently is associated with 
oligohydramnios and fetal growth restriction (16,31).  
 
Described as one of the most significant causes of maternal morbidity and perinatal mortality, 
placental abruption is defined as partial or complete separation of a normally implanted 
placenta before delivery occurs (14). Bleeding then follows from the decidua basalis, between 
the placenta and uterine wall. The combination of pre-eclampsia and placental abruption 
results in significant maternal morbidity, with hypovolaemia, coagulopathy and renal failure 
(32).  
 
A Finnish overview in 2010 reported that the overall prevalence of placental abruption in all 
pregnancies varies from 0.4-1.0% (14). The occurrence tends to decrease with advancing 
gestation. One prospective case series in Tygerberg Hospital, Cape Town reported a 
prevalence as high as 20.2% in women with severe pre-eclampsia between 24 and 34 weeks’ 
gestation (11). Some studies have shown that women with chronic hypertension have a 2.4-
fold increased risk for abruption compared to those without, which increases to 2.8-7.7-fold 
with superimposed pre-eclampsia or fetal growth restriction (32).  A study in Norway showed 
an association of pre-eclampsia with placental abruption with an odds ratio for abruption 
ranging from 1.9 in mild pre-eclampsia to 4.1 in severe pre-eclampsia (33). The literature 
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suggests that of all risk factors, hypertensive disorders ranks the highest on the list for 
placental abruption.  
 
2.4 Neonatal complications 
Perinatal mortality is high in pre-eclamptic women and increases with eclampsia (3). 
Together, pre-eclampsia and eclampsia account for a quarter of stillbirths and neonatal deaths 
in developing countries. The perinatal mortality rate for pregnancies complicated by pre-
eclampsia is three times higher in developing countries than in higher income regions (3). 
 
A retrospective study at Tygerberg and Paarl Hospitals, Western Cape, from 2005-2006 
studied 264 women with late-onset pre-eclampsia (≥34 weeks) and showed a mean 
gestational age at the time of diagnosis of 37 weeks, with a median birth weight of 2700 g. 
There were no early neonatal deaths. Of the five intra-uterine deaths, all due to placental 
abruption, only two occurred at ≥37 weeks. Sixty-nine babies (26%) required admission for 
special neonatal care, a much greater proportion than would be expected from pregnancies at 
≥34 weeks’ gestation not affected by pre-eclampsia.  However, the author did not state how 
many of these admissions were delivered to pre-eclamptic women at ≥37 weeks (34).  
 
A study in the United Kingdom showed that 34.6% of 1087 pre-eclamptic women delivered 
after 37 weeks (22). Serious complications were reported in 151 (13.9%) of the pre-eclamptic 
patients. Of the 382 babies born after 37 weeks gestation, 14.7% required neonatal admission. 
Despite the fact that the focus of the study was on general outcome and not specific to 
gestational age, it does show that a significant number of babies born after 37 weeks gestation 
are admitted to neonatal units. This observation has also been stated by Sibai (35) and 
supports the need for more research to find out why this is the case. 
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The most important factor for survival of a healthy baby is gestational age (36). In a study 
from Tygerberg Hospital comparing expectant management to immediate delivery in severe 
early-onset pre-eclampsia, gestational age was the dominant consideration, with elective 
delivery often decided on after 34 weeks gestation (36). Although most pregnancies were 
remote from term, the study showed an increased survival rate at greater gestations, from 
72% at 28 weeks to 92% at 29 weeks (36). This factor is further supported by data from the 
study mentioned above from Tygerberg and Paarl Hospitals on late-onset pre-eclampsia, in 
which there were no neonatal deaths (34). 
 
A three-year prospective cohort study in Ireland from 1997-2000 on term patients confirmed 
that pre-eclampsia is associated with neonatal encephalopathy (37). One third of the 
encephalopathic babies, associated with hypoxaemia, were born to pre-eclamptic women at 
term. The mean umbilical cord arterial pH was lower in the babies born to pre-eclamptic 
mothers. The authors concluded that the fetuses of pre-eclamptic women may be hypoxaemic 
resulting from poor utero-placental perfusion (37).  
 
While much of the above data are useful, it remains evident that overall the literature lacks 
studies specifically exploring the outcome of babies delivered to pre-eclamptic women at 
term.   
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2.5 Clinical management 
The management of pre-eclampsia is subdivided according to severity of the disease.  There 
is evidence that a patient with mild pre-eclampsia can be managed expectantly until fetal 
viability is reached. As long as she is treatment-compliant and there is no change in her 
clinical and laboratory parameters, the patient can be managed as an outpatient at a day unit, 
which would exist in most facilities in developed countries. However, in South Africa, 
admission to hospital is advised for all pre-eclamptic women using public service facilities 
(7). There must be close maternal and fetal evaluation as life-threatening severe pre-
eclampsia can develop within a short space of time (6,21,38).  
 
On admission to hospital, maternal evaluation consists of investigations to confirm or exclude 
worsening pre-eclampsia. This includes laboratory investigations to observe haematological, 
hepatic and renal function, as well as 12-24 hour urine collection for protein (6). Anti-
hypertensive treatment should commence promptly. The Royal College of Obstetricians & 
Gynaecologists(RCOG) recommend emergency anti-hypertensive agents when BP ≥160/110 
mmHg, and the American College of Obstetricians and Gynecologists(ACOG) recommends 
treatment for diastolic blood pressure levels of ≥105-110 mmHg (6,38). The University of the 
Witwatersrand (Wits) protocol adopted by academic hospitals in Johannesburg, including 
RMMCH, recommends emergency treatment at a BP ≥170/110 mmHg (7). In a case of acute 
severe hypertension, the aim of emergency treatment is to gradually bring down the blood 
pressure so that cerebral autoregulation is not compromised (21). Decreasing the blood 
pressure too quickly may cause uteroplacental hypoperfusion with fetal distress, or maternal 
cerebral ischaemia. Hydralazine, labetalol, or nifedipine are used for the acute management 
of hypertension, with methyldopa being the cornerstone for long term control (29,38,39).  
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It is vital that strict fluid balance is maintained.  Due to the risks of fluid overload and 
pulmonary oedema, total fluid input should be limited to 85 mL/hour. It must also be taken 
into consideration that parenteral anti-hypertensive agents can cause a sudden drop in blood 
pressure; hence, preloading with 500 mL crystalloid fluid may be of value (38).  
 
Although there are different schools of thought regarding the use of magnesium sulphate for 
prevention of seizures, the Wits protocol supports its use for patients with severe or  
imminent eclampsia, as does the RCOG. Certain factors must be taken into consideration 
when administering magnesium sulphate, such as awareness of toxic effects such as 
hypotension, depression of reflexes, respiratory depression and cardiac arrest, for which the 
antidote calcium gluconate must be readily available (7,29,38,39). 
 
The decision to deliver the baby is multifactorial, wherein maternal and fetal wellbeing, past 
obstetric history and current gestation need to be considered. By the Wits protocol and 
supported by the National Institute for Health and Care Excellence (NICE) guidelines in the 
United Kingdom, patients with severe pre-eclampsia are delivered at 34 weeks gestation or an 
estimated fetal weight of 1.5 kg after administration of steroids for accelerating fetal lung 
maturity (6,7,39). The NICE guidelines advise that delivery can also be offered to pre-
eclamptic women with mild to moderate hypertension at 34 to 36 completed weeks 
considering maternal and fetal conditions, risk factors and availability of neonatal facilities. 
Patients from 37 weeks and 0 days should be offered delivery within 24-48 hours (39). There 
is no justification in prolonging a term pregnancy with pre-eclampsia of any severity.  
 
Irrespective of gestational age, delivery generally needs to be expedited in women with 
severe pre-eclampsia, poorly controlled BP requiring more than three agents, persistent 
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imminent eclampsia after administration of magnesium sulphate, HELLP syndrome, 
eclampsia, cerebral oedema, end-organ damage, intrauterine growth restriction, 
oligohydramnios, fetal distress, intra-uterine fetal death or placental abruption (6,38,39). 
 
2.6 Mode of delivery 
The operative delivery rate is increased in patients with hypertensive disorders and more so in 
patients with complicated pre-eclampsia (10). However, there are retrospective studies which 
have shown that induction of labour is not harmful to low birth weight infants. Vaginal 
delivery can be recommended for selected patients with severe pre-eclampsia who have no 
obstetric indication for caesarean section (10). However, a recent prospective study showed a 
four-fold increased risk of failed induction and a two-fold increased risk of caesarean section 
in pre-eclamptic women (31). 
 
In the event of eclampsia, due to the unfavourability of the cervix and the need to deliver 
timeously, the caesarean section rate increases, documented to be 84.8% in a three-year 
review in Nigeria (25). There are no randomized clinical trials exploring the optimum mode 
of delivery in patients with severe pre-eclampsia (6). The decision to deliver by caesarean 
section should be individualized (6). 
 
2.7 The pre-eclamptic patient at term 
As stated earlier, there are few studies specifically focusing on pre-eclampsia and its 
management at term, although data are available on term subgroups in studies on pre-
eclampsia at all gestations. 
18 
 
A retrospective cohort study carried out in 35 hospitals in Canada from 1991-1996 compared 
the birth weights of babies born to pre-eclamptic patients, to those born to normotensive 
patients from 32 weeks up to 42 weeks gestation (8). The authors looked at all babies 
delivered before 37 weeks gestation, and showed that those born to the pre-eclamptic mothers 
had lower birth weights compared to those born to normotensive mothers (p<0.01), after 
adjusting for confounding factors (smoking, maternal age, parity, obesity, prior small-for-
gestational-age, prior large-for-gestational-age, anaemia and premature rupture of 
membranes). However, the babies born at ≥37 weeks’ gestation showed no statistically 
significant difference in mean birth weights when comparing both categories of patients. 
Contrary to common belief, the pre-eclamptic patients who carried to beyond 42 weeks 
gestation delivered babies that had a higher mean birth weight than those delivered to 
normotensive mothers, but the difference was not statistically significant. The focus of the 
study was the association of birth weights with gestation in pre-eclampsia, so there was no 
mention of any maternal or fetal morbidity. However, it can be deduced that babies born at 
term to pre-eclamptic women may have birth weights that are no different from those born at 
term to women who do not have pre-eclampsia. Interestingly, a significant proportion of pre-
eclamptic patients (72%), carried uneventfully to term. Neither the gestation at the time of 
diagnosis nor the severity of the disease was mentioned. However, the study questions the 
hypotheses on the pathophysiology of pre-eclampsia. The findings contest the accepted 
ischaemic model, which states that there is decreased uteroplacental perfusion, as these 
patients, with pre-eclampsia at term, had a normal and perhaps even increased blood flow in 
the majority of cases.  
This outcome suggests a heterogeneity in the pathogenesis of pre-eclampsia, that pre-
eclampsia may manifest in two forms: 1) a restricted fetal growth early-onset pre-eclampsia, 
where affected patients deliver before term and are more likely to have decreased 
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uteroplacental perfusion; and 2) a normal fetal growth late-onset pre-eclampsia, with patients 
often presenting at and delivering at term, likely to have normal uteroplacental perfusion. 
This theory is supported by a retrospective cohort analysis that was carried out in pre-
eclamptic patients in Missouri, USA (40), where ischaemic placental disease was more 
frequent at pre-term than at term gestation (16% versus 5.5% respectively). Again, this 
suggests different pathophysiological pathways between term and preterm pre-eclampsia and 
hence a heterogeneity of the disease process. While this is a clinically evident heterogeneity, 
no studies support the presence of different microvascular or molecular pathogenetic 
processes between early-onset and late-onset pre-eclampsia.   
A critical review in 2011 supports the above hypothesis that early- and late-onset pre-
eclampsia are two distinct diseases, characterized by different biochemical markers, risk 
factors, clinical features and haemodynamic states.  Early-onset pre-eclampsia is described to 
have a comparatively more severe disease profile than late-onset pre-eclampsia, with a 
stronger association with abnormal placentation, increased risk of multi-organ involvement, 
and adverse maternal and fetal outcome. However, due to the lack of studies and reviews no 
criteria have been established to define the two entities. More research is required to clarify 
the differences or similarities between the two groups(41).  
The differing pathophysiology in the above two groups of patients has been further 
investigated and supported in a local prospective case-control study in Tygerberg Hospital 
done in 2007 (42).  The study showed that the placentas of patients with early-onset pre-
eclampsia weighed significantly less and had more ischaemic lesions when compared to those 
of pre-eclamptic women at term (42).  Although the authors described the placentas of late-
onset pre-eclamptic pregnancies as healthy,  placental abruption in this group was still a 
frequent occurrence (eight out of 25 cases). 
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The HYPITAT Study was a European multicentre randomised controlled trial that 
investigated treatment of patients with gestational hypertension and mild pre-eclampsia at 36 
to 41 weeks gestation, from 2005-2008 (43). Patients with severe pre-eclampsia were 
excluded. The aim was to compare induction of labour with expectant management in 
patients with mild pre-eclampsia and gestational hypertension beyond 37 weeks’ gestation. 
Although there were no maternal deaths, there was a high rate of morbidity. Of 756 women, 
30% developed severe hypertension, and 15 patients (2%) developed HELLP Syndrome, 
10% had postpartum haemorrhage and 2 patients (0.2%) had pulmonary oedema. The 
expectant management group included 11 of the 15 women who developed HELLP 
syndrome, as well as both patients that developed pulmonary oedema. No patient had 
placental abruption. Eighty-eight women in the induction group compared to 138 women in 
the expectant management group progressed to severe disease. The study showed that 
prolonging pre-eclampsia beyond 37 weeks added significant risk for maternal morbidity. 
The study did not look at the outcome of pre-eclampsia at term per se, and perhaps merging 
both pre-eclampsia and gestational hypertension was a weakness of this study. The 
HYPITAT study data certainly show that there is a high rate of maternal morbidity in pre-
eclamptic patients at term. Morbidity rates for pre-eclampsia are likely even higher than 
found in the study, because of the merging of gestational hypertension with pre-eclampsia, 
and because severe disease and pre-eclampsia complications were part of the exclusion 
criteria for the study.  
 
A 10-year cross-sectional retrospective study of 685 pre-eclamptic pregnancies from Saudi 
Arabia showed that 31% of stillbirths, and one out of seven neonatal deaths were in babies 
who were delivered at term to pre-eclamptic patients (9). Placental abruption, renal failure, 
coagulopathy and HELLP syndrome were the major maternal complications recorded. There 
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were two maternal deaths. Mild pre-eclamptic patients were managed expectantly and severe 
pre-eclamptics managed by immediate delivery. About 70% of the pre-eclamptic women 
delivered after 37 weeks. Whether these patients had mild pre-eclampsia and were managed 
expectantly up to term, or whether they were patients who presented at term with severe 
disease is unclear. Nevertheless, this is one of only a few studies where such a large number 
of pre-eclamptic mothers carried to term. Unfortunately the details of the outcome of the 
women at term were neither analysed nor reported on separately, and therefore cannot be 
commented on with respect to morbidity and mortality of the mothers and babies(9).  
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3.0 PROBLEM STATEMENT AND OBJECTIVES 
Pre-eclampsia, as part of the hypertensive disorders of pregnancy, is the second most 
common cause of direct maternal mortality in South Africa. Being a disease that is exclusive 
to pregnancy, it is well known that delivery is the only cure.  
 
Conflicting findings of fetal outcomes, and potentially poor maternal outcome even as one 
approaches term in pre-eclampsia, is what can be gathered from the relevant literature. 
Having reviewed the literature above, it becomes evident that there is a deficiency of data 
regarding the outcome of pre-eclamptic pregnancies at term. It appeared to be a feasible task 
to indulge in the wealth of information that patients offer at RMMCH, to fill in some 
evidence gaps regarding pre-eclampsia at term. 
 
In a tertiary institution such as RMMCH, it was expected that patients with both mild and 
severe pre-eclampsia were treated in the facility. In addition, RMMCH delivers almost all 
women from its catchment area. These considerations made it feasible to study the prevalence 
of pre-eclampsia in this area, in the absence of significant referral bias.  
 
3.1 Objectives of this study 
1. To determine the prevalence of pre-eclampsia at term at RMMCH 
2. To describe demographic and clinical factors in women with pre-eclampsia at term 
3. To assess the severity of maternal disease in term pre-eclamptic patients 
4. To assess the fetal outcome of pregnancies with pre-eclampsia at term  
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4.0 METHODS 
4.1 Study design and study population 
This was a prospective cross-sectional, descriptive study, carried out over a period of six 
months using a period sample. All women at term (≥37 weeks gestation by best estimate) 
who were admitted for pre-eclampsia were entered into the study and followed up until 
delivery. Patients who were admitted before term but delivered after 37 weeks were also 
entered into the study. Patients who did not attend antenatal clinic (unbooked women) were 
not included in the study because a true diagnosis of pre-eclampsia could not be made 
without a prior blood pressure assessment.  
 
The definition of pre-eclampsia used in this study and endorsed by the ISSHP (International 
Society for the Study of Hypertension in Pregnancy) is described as the development of 
hypertension with proteinuria after 20 weeks gestation, which returns to normal postpartum. 
For women who booked after 20 weeks (a common occurrence in the population using 
RMMCH), a normal blood pressure and absence of proteinuria that preceded the onset of pre-
eclampsia allowed classification of the patient as pre-eclamptic. Proteinuria was defined as 
≥1+ on urine dipstick, or a spot protein/creatinine ratio ≥30 mg/mmol. Postpartum resolution 
of the hypertension and proteinuria could not be confirmed in this study. 
 
4.2 Setting 
This study was conducted in the obstetric unit at RMMCH, a district and regional hospital 
with tertiary functions, affiliated with the University of the Witwatersrand as a teaching 
hospital. The hospital delivers about 1000 women each month and only rarely refers difficult 
obstetric patients to other hospitals. It has only one referring midwife obstetric unit 
(Discoverers Clinic), which delivers about 60 women each month. The protocol guiding care 
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at RMMCH states that all women with pre-eclampsia, irrespective of gestational age, are 
admitted to hospital. Patients with mild pre-eclampsia are delivered if they reach term or if 
they present at term (7).   
 
4.3 Sample size 
It was hoped that 100 women could be included in the study, to allow a precision with a 95% 
confidence interval of at most 10% around observed proportion estimates.  
 
4.4 Data collection 
Every term pre-eclamptic patient admitted from 1 November 2012 to 30 April 2013 was 
entered into the study. After receiving informed consent from the participating patient, the 
researcher extracted the demographic and clinical data from the patient’s clinical file. The 
antenatal information was entered into the study data sheet immediately, and then the notes 
were followed prospectively up to delivery and postpartum. If a woman had already delivered 
by the time the researcher saw her for the first time, or a woman was admitted before term 
but delivered after 37 weeks, the information was entered retrospectively from the case notes.  
Explanatory variables that were collected included age, parity, gravidity, and a history of 
previous pre-eclampsia. The recorded details of the current pregnancy included the gestation 
at, and mode of delivery, as well as the birth weight and Apgar scores of the baby. The length 
of stay in hospital for the baby and the mother were also noted.  
Consent from the 16 year old patient was taken after explaining the purpose of the study to 
her, reassuring her that she will not be re-numerated, nor will she or her baby be exposed to 
any harm, in layman’s terms in her language with the aid of a nursing staff member.  An 
opportunity was also allowed for her to raise any questions or concerns, and to reiterate what 
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was explained to her to reflect her understanding of the consent and her participation in the 
study.  
The outcome variables that were analysed were broadly divided into maternal and fetal. 
Maternal variables included severe hypertension (defined as a systolic BP≥160 mmHg or 
diastolic BP≥110 mmHg, on two occasions four hours apart or a single diastolic BP≥120 
mmHg), eclampsia, pulmonary oedema (diagnosed clinically or radiographically), placental 
abruption (clinical diagnosis and  macroscopic examination of placenta) and HELLP 
syndrome. Patients were classified as having HELLP syndrome by establishing the presence 
of thrombocytopaenia (platelet count <100x10
9
/L) and raised ALT or AST levels (>40 IU/L). 
Fetal and neonatal outcomes were obtained from the delivery notes or the neonatal admission 
file if the baby was admitted. The fetal outcome variables included stillbirth, birth weight, 
Apgar scores, neonatal unit admission with reason, and neonatal death. The data collection 
sheet is attached as Appendix I. 
 
4.5 Data analysis 
Descriptive statistical methods were used, including statements of summary measures such as 
means, standard deviations, medians and ranges. Proportions were expressed as percentages. 
Analytic statistical methods were not employed.  
 
4.6 Ethics 
This study received approval from the University of the Witwatersrand Human Resources 
Research Ethics Committee, approval number M121060 (Appendix II). All participant 
information was kept confidential, and data sheets did not include any unique identifiers such 
as the patient’s name, birth date, hospital number or address. Hospital permission was 
obtained from the Chief Executive Officer of RMMCH. 
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4.7 Funding 
Data capturing was conducted by the researcher and processed with the help of the 
supervisor. The researcher incurred all costs concerned. 
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5.0 RESULTS 
5.1 The prevalence of pre-eclampsia at term at RMMCH 
There were 6300 deliveries during the period 1 November 2012 to 30 April 2013. Seventy-
eight women were diagnosed with pre-eclampsia and delivered at term, and were recruited 
for the study. Therefore, the prevalence of patients with pre-eclampsia who delivered at term 
at RMMCH was 1.2%.  
 
5.2 Demographic and clinical factors in women with pre-eclampsia at term 
Basic demographic and clinical information is shown in Table 2.  
The oldest patient in the study was aged 43 years, and the youngest was 16 years old. The 
mean age of the women was 27.3 years with a standard deviation (SD) of 5.8 years; 11.5% of 
women were older than 35 years. The median parity was one, with 35 primigravid women 
and six women having a parity of three or more. The parity range in this sample was zero to 
four. The median gestational age at delivery was 38 weeks. Gestational age was calculated by 
last normal menstrual period in 44 women (56.4%), with only 17 (21.8%) having had an early 
ultrasound scan (≤24 weeks). Twelve patients had a late ultrasound scan and five patients 
were dated by clinical palpation. Two patients in the study had pre-eclampsia previously. 
There were three pairs of twins.  
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Table 2: Demographic and clinical factors of women with pre-eclampsia at term (n=78) 
   No. %  
Age (years) ≤18  4 5.1  
 19-34  65 83.3  
 ≥35  9 11.5  
      
Parity 0  35 44.9  
 1  22 28.2  
 2  15 19.2  
 ≥3  6 7.7  
      
Antenatal 
booking (weeks) 
<20   22 28.2  
 ≥20   56 71.2  
 
Gestational age 
at delivery 
(weeks) 
 
 
Previous  
pre-eclampsia 
 
Twin pregnancy 
 
 
37 
38-40 
≥41 
 
 
 
 
  
26 
47 
5 
 
 
2 
 
 
3 
 
 
33.3 
60.3 
6.4 
 
 
2.6 
 
 
3.9 
 
 
 
 
A summary of clinical management of the pre-eclamptic patients is shown in Table 3. A 
variety of antihypertensive drugs was used, the most frequent being short-acting nifedipine 
(n=72; 93%). It was not always possible to distinguish from the notes whether this 
medication was given for acute BP lowering or for BP control maintenance, since it was used 
for both reasons during the study period. Both long-acting nifedipine and methyldopa were 
used for BP control maintenance. Intravenous labetalol was used for only three patients.  
 
Thirty-eight patients received magnesium sulphate, of who 7 received only a 4 g loading 
dose, and 31 received maintenance dosages beyond the initial loading dose. 
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Fifteen patients went into spontaneous labour, while 28 had labour induced for maternal 
reasons, including two women who were ≥42 weeks’ gestation.  
 
Fifty-one patients (65%) delivered by caesarean section, 52% for maternal reasons, and 48% 
for fetal indications. Although there was an overlap in some patients who required operative 
delivery from both maternal and fetal perspectives, the stronger indication was documented, 
either maternal or fetal. There were no elective caesarean sections in this study.  
 
 
Table 3: Clinical management of women with pre-eclampsia at term (n=78) 
 
   No %  
Anti-hypertensive drugs  
Short acting nifedipine  
  
72 
 
92.3 
 
 Long acting nifedipine  17 21.8  
 MgSO4-loading  38 48.7  
 MgSO4-maintenance  31 39.7  
 Methyldopa  56 71.8  
 Labetalol  3 3.9  
 Amlodipine  1 1.3  
Induction of labour   28 35.9  
Caesarean section      
               Indications:  Maternal  33 52.4  
 Fetal  30 47.6 
 
 
ICU ventilation 
Blood transfusion 
  3 
3 
3.9 
3.9 
 
 
MgSO4=magnesium sulphate; ICU=intensive care unit 
Certain indications for caesarean sections were a combination of maternal and fetal. 
 
 
5.3 The severity of maternal disease in term pre-eclamptic patients 
The complications of the pre-eclamptic patients are summarised in Table 4. Severe 
hypertension occurred in 59 (76%) of the women. Imminent eclampsia was recorded in 29 
(37%) of patients and 9% of women had eclamptic convulsions. There was some overlap 
where patients had more than one complication. Six patients developed pulmonary oedema, 
three of whom required intensive care and ventilation, provided in the obstetric high care area 
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as there were no beds available in the ICU. One of these patients developed pulmonary 
oedema in the antenatal ward and died shortly after delivering spontaneously, and is 
described in detail below. 
 
Two patients had both eclampsia and pulmonary oedema, one of whom had to be intubated 
and ventilated. There were 13 patients with isolated thrombocytopenia and three had true 
HELLP syndrome by definition. 
 
Three patients required blood transfusions for postpartum haemorrhage (PPH). One of these 
patients had a placental abruption, the second patient a retained placenta and the third patient 
had anaemia antenatally. They each received at least two units of red blood cells. No patient 
in this study had an intra-cerebral haemorrhage. 
 
The median number of days admitted to hospital was five, with a range of 1-11. One patient 
stayed in hospital for 11 days as she was diagnosed with hyperthyroidism and was being 
investigated by internal medicine specialists. 
 
 
Table 4: Maternal morbidity and mortality in pre-eclamptic women at term (n=78)  
 
Complication*  No. %   
Severe hypertension  59 75.6   
Imminent eclampsia  29 37.2   
Eclampsia   7 9.0   
HELLP Syndrome  3 3.8   
Pulmonary oedema  6 7.7   
PPH  3 3.9   
Abruptio placentae  1 1.3   
Renal Failure  1 1.3   
Death   1 1.3   
*Patients may have more than one complication each 
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Haematological and biochemical indices were documented at their highest level during the 
hospital admission and are shown in Table 4. For three patients, no blood results could be 
found.  Twenty-two patients (29%) were anaemic (Hb ≤11.0 g/dL). The median haemoglobin 
level was 11.6 g/dL with a range of 6.2-16.3 g/dL. 
Thirteen patients (17%) had low platelet counts (<150x10
9
/L), with five patients having 
moderate thrombocytopenia. None had severe thrombocytopenia. The median creatinine level 
was 64.2 μmol/L, with a range of 27-153 μmol/L (a threshold of 100 mmol/L was used to 
define renal dysfunction as per the institution’s protocol ). There was one patient who had 
renal failure based on oliguria, but she died before she required dialysis. One patient had a 
markedly elevated ALT reported as 10000 IU/L. Nine patients had abnormal AST levels 
ranging from 42-643 IU/L. 
 
Table 5: Haematological indices in pre-eclamptic women at term (n=75*) 
 
 No. %    
Haemoglobin (g/dL) 
6.0-8.0 
 
4 
 
5.3 
   
8.1-10.0 6 8.0    
10.1-11.0 12 16.0    
11.1-13.0 39 52.0    
≥13.1 14 18.7    
      
Platelet count (x10
9
/L)      
>150 62 82.7    
100-150 8 10.7    
50-100 5 6.7    
<50 0 0    
      
Creatinine levels(μmol/L)      
<60 37 50.0    
60-100 31 41.9    
>100 6 8.1 
 
 
   
Urea levels(mmol/L)      
<4.5 65 87.8    
4.5-10 9 12.2    
Highest levels during admission were documented 
*Blood results were unavailable for three patients 
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5.4 The fetal outcome of pregnancies with pre-eclampsia at term  
Eighty-one babies were delivered, including three pairs of twins. One baby was lost to follow 
up and its details were not captured. The mean birth weight was 2695 g with a range of 1600 
g to 5245 g. Fourteen were admitted for a median number of 2.5 days, with an interquartile 
range of 0-1. Two babies were admitted for meconium aspiration. Six were admitted for 
respiratory distress, all of whom were delivered by caesarean section. All but one of these six 
caesarean sections was done for fetal distress.  
 
Three babies were admitted for birth asphyxia. The first baby was born to a 26 year old 
woman who had booked after 20 weeks’ gestation, with prior evidence of normal blood 
pressures and no previous pre-eclampsia. She had carried her pregnancy to 43 weeks by 
dates, and presented with severe hypertension, HELLP syndrome and placental abruption. 
The baby was delivered by emergency caesarean section for both maternal and fetal reasons. 
The baby weighed 3120 g and had an Apgar score of 6 at 5 minutes. The baby was diagnosed 
with birth asphyxia but did not develop Hypoxic Ischaemic Encephalopathy (HIE). He was 
admitted for observation and discharged on the next day. The second baby admitted for 
asphyxia was born to a 27 year old woman who booked after 20 weeks’ gestation and had 
normal blood pressures prior to admission. She was admitted at 39 weeks’ gestation with 
severe hypertension and imminent eclampsia and was maintained on magnesium sulphate. 
Following induction of labour, fetal distress developed, necessitating caesarean section. The 
baby weighed 3330 g and had an Apgar score of 7 at 5 minutes. He required intubation for 
apnoea. He was diagnosed with HIE I but discharged nine days later. The third baby was born 
by spontaneous labour to a 16 year old patient who booked before 20 weeks’ gestation and 
had no complications of pre-eclampsia. The baby weighed 3595 g, with an Apgar score of 8 
at 5 minutes. The baby was admitted for three days for HIE I, and then discharged. There 
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were no stillbirths. There was one neonatal death from meconium aspiration born to the 
patient who died, as discussed below. 
 
Table 6: Fetal outcome in term pre-eclamptic patients (n=80*) 
 
 No. %    
Birth weight (g):   
             1500-1999 
 
3 
 
3.8 
   
             2000-2499 15 18.8    
             2500-2999 26 32.5    
             3000-3499 25 31.3    
             ≥3500 11 13.8    
Neonatal unit admissions 14 17.5    
Meconium aspiration 2 2.5    
Birth asphyxia  3 3.7    
Respiratory distress 6 7.5    
      
Neonatal jaundice and LBW 2 2.5    
Neonatal death 1 1.3    
*Includes 3 pairs of twins and one singleton for whom there were no data. 
 
 
5.5 Maternal death 
There was one maternal death in this study. She was a 28 year old para 2 at 38 weeks 
gestation by palpation. She booked after 20 weeks gestation, with no evidence of 
hypertension on her early visits. Her previous pregnancies were uneventful with no pre-
eclampsia. She was admitted with severe hypertension, for BP control and delivery. During 
her stay in the antenatal ward she developed respiratory distress, which was initially mild but 
then worsened such that she was moved to the high care area for intensive management. She 
was treated for pulmonary oedema with intravenous furosemide, with minimal response. She 
was also oliguric and had serum urea and creatinine levels of 11.3 mmol/L and 128 μmol/L 
respectively. Simultaneously, she was found to be in labour, which progressed to the delivery 
of a live baby weighing 2440 g. There was meconium passage in utero and the baby 
aspirated. The baby had a recorded Apgar score of 8 at 5 minutes but died shortly after birth. 
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After delivery, the patient’s condition deteriorated to the point that she needed intubation and 
ventilation for refractory pulmonary oedema. With no ICU beds available, the resuscitation 
was performed in the high care area. Once she was stabilized with the support of inotropic 
drugs, a CT scan of the brain was arranged, which showed cerebral oedema but no 
intracranial haemorrhage. Almost 24 hours later, still on inotropes, the patient died. An 
autopsy was not done. 
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6.0 DISCUSSION 
This study has found that significant morbidity accompanies pre-eclampsia at term, especially 
in terms of maternal complications. With seven cases of eclampsia and six cases of 
pulmonary oedema including one maternal death, the risks of pre-eclampsia at term should 
not be underestimated. Conversely, there appeared to be low morbidity and mortality in the 
newborn infants.  
 
 
6.1 The prevalence of pre-eclampsia at term at RMMCH 
This study showed a prevalence of pre-eclampsia at term of 1.2%. This estimate is likely to 
be close to a true prevalence because of the low likelihood of referral bias at RMMCH. The 
only missing numbers from the prevalence denominator are an approximate 360 births at 
Discoverers Clinic. Including these numbers in the denominator, assuming that no pre-
eclamptic women delivered at that clinic (the protocol is to transfer such women to 
RMMCH), the adjusted prevalence remains 1.2% - a decrease from 1.24% to 1.17%.    
 
The global impact of pre-eclampsia is 2-8% of pregnancies with a reported prevalence of 5-
8% in the USA (3,6). The prevalence in this study may appear low relative to the statistics 
mentioned above, but it must be borne in mind that this is representative of a pre-eclamptic 
population at term, and excludes pre-eclamptic women before 37 weeks’ gestation. The 
statistics in the literature do not differentiate between term and pre-term pregnancies. 
Considering this fact, one is led to believe that a significant proportion of our pre-eclamptic 
patients make it to term or that many cases of pre-eclampsia only manifest clinically at term. 
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6.2 Clinical factors in women with pre-eclampsia at term 
A variety of drug treatments was employed for treatment of hypertension. This may be 
attributed to rotation of junior and trainee staff from different medical institutions in 
Johannesburg, resulting in different approaches to the acute management of the hypertension 
in pre-eclamptic patients at term and deviations from the protocol at RMMCH. 
Unfortunately, the use of nifedipine for acute blood pressure lowering could frequently not be 
distinguished from maintenance treatment of hypertension. However, the frequent use of 
magnesium sulphate does indicate the clinical concern for the women that were included in 
this study. Despite 48.7% of women being loaded with and 40% of patients being maintained 
on magnesium sulphate , 9% complicated with eclampsia. In those patients who developed 
eclampsia, the data sheet did not stipulate whether the patient had received magnesium 
sulphate prior to the eclamptic episode. However, two out of seven eclamptic patients were 
not documented as imminent eclampsia. From that one can deduce that the magnesium 
sulphate was given as treatment of the eclampsia and not as prophylaxis. In general, 
clinicians at RMMCH do not use magnesium sulphate in pre-eclampsia unless the condition 
is considered severe or suggestive of imminent eclampsia. Perhaps this high incidence of 
eclampsia then should prompt a wider prophylactic approach. 
 
6.3 The severity of maternal disease in term pre-eclamptic patients 
Fifty-one patients (65%) delivered by caesarean section, about half for maternal reasons, and 
half for fetal indications. Although vaginal delivery is preferred for maternal considerations 
in pre-eclamptic woman, the caesarean section rate was high even for maternal indications 
and comparable to that experienced in Tygerberg Hospital,  but similarly having a higher rate 
for maternal than for fetal indications (34). Studies have shown that there is an increased risk 
of failed induction and caesarean section in pre-eclamptic women (31). The study at 
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Tygerberg Hospital supported this finding by showing that 50% of their caesarean sections 
were performed for failed induction of labour or fetal distress after induction of labour(34). 
Short-term morbidity after caesarean section was not a significant problem, but long-term 
problems such as wound haematoma (possibly related to thrombocytopaenia) and subsequent 
wound sepsis could not be studied, because patients were not followed up through the 
puerperium. 
 
Severe hypertension was diagnosed in about three quarters of the patients. Imminent 
eclampsia was recorded in 37%, all of whom received magnesium sulphate. Nine per cent of 
the patients complicated with eclampsia. This and the high proportion of women with severe 
hypertension, reflects the significant morbidity endured in pre-eclamptic patients at term. A 
9% rate of eclampsia in a 1.2% proportion of cases of pre-eclampsia at term suggests an 
eclampsia rate at term of one in 1000 pregnancies, much higher than the two to three cases 
per 10 000 for eclampsia (at all gestational ages) quoted for developed countries (3). A 
comparable eclampsia rate for term pregnancies is not available in the literature.  Related to 
eclampsia, intra-cerebral haemorrhage is an important cause of maternal mortality in South 
Africa (29). However, there were no cases of intra-cerebral haemorrhage in this study.   
 
Compared to a reported prevalence of 0.08-0.5% (30), 7.7% of pre-eclamptic women at term 
in the current study complicated with pulmonary oedema, half of whom had to be intubated 
and ventilated and required intensive care, with one death. The author speculates that perhaps 
an obstetric critical care unit would have added much value to the management and outcome 
of these patients, particularly the patient who developed pulmonary oedema while admitted in 
the ward. The complication could have been detected earlier and promptly managed if she 
was in a critical care setting. Again, extrapolating from the 1.2% prevalence of pre-eclampsia 
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at term, the prevalence of pulmonary oedema at term here would be about 1:1000 
pregnancies, much higher than the 1.2 per 10 000 deliveries reported in the United Kingdome 
(22). The finding is even more concerning when one remembers that the United Kingdom 
rate is for pregnancies of all gestational ages and for all causes of pulmonary oedema, not 
only pre-eclampsia.  
 
In this study one patient had a placental abruption, in keeping with the national prevalence of 
0.5-2% (18).  However, the sample size was too small to make any conclusion about the 
frequency of abruption in association with term pre-eclampsia, other than to state it was not a 
common finding. From the available data on these patients, there seemed to be little evidence 
of placental disease, suggesting that term pre-eclamptic patients perhaps have predominantly 
maternal disease with relatively few placental and fetal adverse events, in keeping with recent 
observations regarding late-onset versus early-onset pre-eclampsia(34,41,42,44). However, 
growth restriction diagnosis was rarely attempted in these patients and formal screening for 
small-for-gestational-age was not performed on the babies after delivery. The observed 18% 
rate of low birth weight babies could suggest placental insufficiency or misclassified 
gestational age.  
 
Thirteen patients had thrombocytopenia, some of whom were managed as HELLP syndrome 
based on their clinical status. This number is not included in the group of patients 
documented with true HELLP syndrome. The prevalence of true HELLP syndrome by 
definition was 3.8% in this study, lower than the reported prevalence of 20% in severe pre-
eclamptic patients as quoted by Curtain and Weinstein (18), but similar to the 5.2% found at 
Tygerberg Hospital (11). Contrary to the haemoconcentration found in patients with pre-
eclampsia, 29.3% of women had a haemoglobin level ≤11.0 g/dL on admission. Neither the 
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type nor the cause of the anaemia was a focus of the study and therefore was not documented. 
All patients who are booked at the antenatal clinics receive iron and folate. Therefore, the 
question of anaemia and its association with HIV and anti-retroviral drugs, or other factors, 
comes into question. However, the HIV status of the women was not recorded in the data.    
 
6.4 The fetal outcome of pregnancies with pre-eclampsia at term 
The major fetal complications encountered were meconium aspiration, from which one baby 
died, respiratory distress and birth asphyxia. All babies admitted for respiratory distress were 
delivered by caesarean section, of which all but one was for fetal distress. This leads one to 
question whether the respiratory distress was due purely to the placental insufficiency with 
metabolic acidosis related to pre-eclampsia, misclassification of gestational age, or was 
related to caesarean section itself, which is known to be associated with mild respiratory 
distress (45, 46) also associated with borderline maturity at 37-38 weeks (37). The neonatal 
admission rate in this study was high (17.5%), similar to the 14.7% found in the United 
Kingdom (22). It must yet again be remembered that the studies cited encompass all pre-
eclamptic women, whereas this study included only women at ≥37 completed weeks.  As 
noted by Sibai, and evidenced by this study, the majority of neonatal admissions from 
hypertensive mothers are those who are delivered at term. The reasoning is unknown and 
emphasizes the need for research in this area (35). The high caesarean section rate comes into 
question as a possible reason, given the concern about respiratory distress mentioned above. 
 
6.5 Limitations of the study 
The small study population affected the precision of the reported estimates, and rendered it 
difficult to comment on some of the findings. However, the severe outcomes in this study 
such as eclampsia and pulmonary oedema are significant enough to warrant a larger 
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population-based study. The significance of the findings could perhaps have been enhanced if 
the researcher compared them to a control group of term non-pre-eclamptic women and to a 
group of pre-eclamptic women remote from term. The researcher relied on patients’ files for 
recording of clinical observations and bedside investigations. This allowed room for error in 
measurements beyond the control of the researcher, and possible misclassification of 
hypertensive disorders and gestational age. Unbooked patients were excluded from this study 
and therefore those patients who presented for the first time to hospital with unclassified 
proteinuric hypertension or eclamptic episode were not documented. However, in the 
researcher’s experience unbooked women presenting at term are a rarity at RMMCH. It was 
also not possible to document resolution of hypertension after delivery, to exclude chronic 
hypertensive disease misclassified as pre-eclampsia. During the study time period the 
laboratory staff were upgrading their data systems, therefore results were not always readily 
available. Patients were managed on whatever results were available and on their clinical 
condition. Hence, patients with thrombocytopenia were often managed as HELLP syndrome, 
in the absence of certainty about haemolysis. Haematocrit levels are not routinely recorded in 
the patients file, and this posed a limitation to the more accurate assessment of the anaemia 
and haemoconcentration observed.  To the best of the researcher’s knowledge, none of the 
patients entered into the study were referrals, and RMMCH did not refer any hypertensive 
patients to other hospitals, and therefore this sample is likely to be representative of a pre-
eclamptic population at term. Also, in this study, the focus was on outcomes and it is unlikely 
that any serious complications were missed. The likely impact of a gap in the denominator 
resulting from the exclusion of Discoverers Clinic deliveries has been discussed earlier. 
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6.6 Conclusion 
It seems clear that there is a tendency to poor maternal outcome as one approaches term in 
pre-eclampsia. This study demonstrated that maternal complications such as eclampsia and 
pulmonary oedema are common in pre-eclampsia at term. Clinical vigilance and expertise are 
as important for pre-eclamptic women at term as they are for those who are pre-term. The 
importance of maternal stabilization before embarking on delivery or surgery must always be 
considered. 
 
As demonstrated by this study, and suggested by the little data available in the literature, the 
fetal morbidity and mortality seems to be lower in the neonate of a term pre-eclamptic 
woman. This sheds more light on the theory of the heterogeneous pathophysiology of pre-
eclampsia, which may manifest as: 1) a restricted fetal growth syndrome (early-onset pre-
eclampsia), where affected patients deliver before term and decreased uteroplacental 
perfusion may be evident; and 2) a normal fetal growth syndrome (late-onset pre-eclampsia) 
where patients progress to term and have normal uteroplacental perfusion, as supported by 
Dahlia in  a critical review of both early- and late-onset pre-eclampsia(41).  
 
There is a need for a larger epidemiological study where term pre-eclamptic patients can be 
compared to pre-term pre-eclamptic patients. It may also be of value to follow these two 
groups of patients through the pueperium to assess for complete resolution of the 
complications or residual disease subsequent to the severe complications such as pulmonary 
oedema and eclampsia.  
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Appendix I: Data collection sheet 
       
         1.Patient details: 
       Subject no…………….. 
 
Age……….. 
 
Parity………... Gravidity……………… 
         Booked? 
 
Yes/No/Unknown 
 
Previous PET: Yes/No/Unknown 
         Booked before 20 weeks GA? Yes/No If No, was there evidence of previous normotension 
         in the pregnancy? Yes/No 
      
         2. Peripartum 
details: 
       Indication for delivery Maternal/Fetal 
    
         Mode of Delivery 
 
NVD/Caesar 
    
         GA at delivery……………weeks by dates/early ultrasound/late ultrasound/palpation 
 
         
         3. Maternal Complications:  
      
         Severe Hypertension(Systolic BP≥160mmHg, or diastolic BP≥110, on two occasions 
  four hours apart or a single diastolic BP≥120mmHg) 
 
Yes/No 
  
         Immin.Eclampsia Yes/No 
 
Eclampsia      Yes/No 
  
         HELLP Syndrome Yes/No 
 
P.Oedema Yes/No 
  
         PPH 
 
Yes/No 
 
DIC 
 
Yes/No 
  
         P.Abruption Yes/No 
 
Renal Failure Yes/No 
  
         Emergency Hysterectomy  Yes/No 
 
CVA Yes/No 
  
         Subcapsular haematoma Yes/No 
     
         ICU Admission Yes/No 
 
No of days in Hospital…………… 
  
         Death 
 
Yes/No 
      
         
         3.Fetal Complications: 
      
         Live birth/Stillbirth 
  
Birth weight……………grams 
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         Neonatal admission 
 
Yes/No 
 
No of days in hospital………………… 
         
Apgar 
 __ 
/1;__/5;__/10 
 
Diagnosis……………………………….. 
  
         Death 
 
Yes/No 
       
 
Blood results 
       
         Hb…… Hct…… 
 
Urea….. 
 
ALT…… 
   Plts…… 
  
Creat…… 
 
AST…… 
   
         
         Treatment 
       Acute mx of Hypertension 
      
         
         
         
         
         
         
         MgSO4:loading +/- 
maintenance:  
    
   
   
   
   
   
   
   
   
   
   
   
   
Induction of Labour: 
 Yes/No  
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